Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

EFFECT OF ANTIHYPERTENSIVE DEPRESCRIBING ON SERIOUS ADVERSE EVENTS, MORTALITY, AND CARDIOVASCULAR DISEASE: LONG-TERM FOLLOW-UP OF THE OPTIMISE RANDOMISED CONTROLLED TRIAL

Title: EFFECT OF ANTIHYPERTENSIVE DEPRESCRIBING ON SERIOUS ADVERSE EVENTS, MORTALITY, AND CARDIOVASCULAR DISEASE: LONG-TERM FOLLOW-UP OF THE OPTIMISE RANDOMISED CONTROLLED TRIAL
Authors: Sheppard, James; Temple, Eleanor; Wang, Ariel; Smith, Anne; Pollock, Stephanie; Ford, Gary; Hobbs, Richard; Kenealy, Nicola; Lown, Mark; De Lusignan, Simon; Mant, Jonathan; Mccartney, David; Payne, Rupert; Williams, Marney; Yu, Ly -Mee; Mcmanus, Richard
Source: Journal of Hypertension ; volume 42, issue Suppl 1, page e109-e110 ; ISSN 0263-6352 1473-5598
Publisher Information: Ovid Technologies (Wolters Kluwer Health)
Publication Year: 2024
Description: Objective: Deprescribing of antihypertensive medications is recommended for some older patients with polypharmacy and frailty. The OPTIMISE trial showed that this can be achieved without affecting blood pressure control at 3-month follow-up. This longer-term follow-up study aimed to examine the impact on serious adverse events (SAEs), mortality and cardiovascular disease (CVD) outcomes after at least 3 years. Design and method: Participants aged 80 years or older, with systolic blood pressure
Document Type: article in journal/newspaper
Language: English
DOI: 10.1097/01.hjh.0001020408.42462.e5
Availability: https://doi.org/10.1097/01.hjh.0001020408.42462.e5; https://journals.lww.com/10.1097/01.hjh.0001020408.42462.e5
Accession Number: edsbas.D7A3DC76
Database: BASE